Key result
Higher plasma thrombomodulin is linked to increased all-cause and vascular mortality during long-term anticoagulation.
Why the study?
Do plasma levels of thrombomodulin predict mortality in patients on long-term anticoagulant treatment?
Population
209 patients on long-term anticoagulant treatment
Design
Cohort
Follow-up
3.8 years
Authors
Loading...
Should not yet guide anticoagulation decisions; hypothesis-generating for thrombomodulin in mortality risk stratification.
Cohort (n=209)
Do plasma levels of thrombomodulin predict mortality in patients on long-term anticoagulant treatment?
p-value: p=0.025
Increased plasma thrombomodulin levels independently predict all-cause and vascular mortality in patients on long-term anticoagulation.
Jansson et al. (1996) conducted a cohort in Patients on long-term anticoagulant treatment (n=209). Plasma thrombomodulin levels was evaluated on All-cause mortality (p=0.025). Increased levels of plasma thrombomodulin were significantly associated with all-cause (P=0.025) and vascular mortality (P=0.042) in patients on long-term anticoagulant treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: